Titan Pharmaceuticals, Inc. Stock price

Equities

TTNP

US8883147055

Pharmaceuticals

Delayed Nasdaq 01:22:37 2024-03-28 pm EDT 5-day change 1st Jan Change
7.01 USD -5.01% Intraday chart for Titan Pharmaceuticals, Inc. +1.74% -15.03%
Sales 2021 1.53M Sales 2022 557K Capitalization 11.46M
Net income 2021 -8M Net income 2022 -10M EV / Sales 2021 2.87 x
Net cash position 2021 5.74M Net cash position 2022 2.75M EV / Sales 2022 15.6 x
P/E ratio 2021
-1.13 x
P/E ratio 2022
-1.03 x
Employees 4
Yield 2021 *
-
Yield 2022
-
Free-Float 45.69%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.04%
1 week+8.05%
Current month-1.60%
1 month-12.56%
3 months+13.16%
6 months-18.22%
Current year-10.55%
More quotes
1 week
6.28
Extreme 6.28
8.29
1 month
6.28
Extreme 6.28
9.29
Current year
5.25
Extreme 5.25
9.35
1 year
5.00
Extreme 5
16.90
3 years
5.00
Extreme 5
62.00
5 years
5.00
Extreme 5
1 308.00
10 years
5.00
Extreme 5
36 000.05
More quotes
Managers TitleAgeSince
Chief Executive Officer 33 22-08-14
President 63 06-12-31
Members of the board TitleAgeSince
Director/Board Member 71 22-08-14
Director/Board Member 52 22-08-14
Director/Board Member 53 22-08-14
More insiders
Date Price Change Volume
24-03-28 7.01 -5.01% 5 618
24-03-27 7.38 +2.04% 80,733
24-03-26 7.233 +5.59% 12,033
24-03-25 6.85 +8.90% 5,315
24-03-22 6.29 -8.71% 9,853

Delayed Quote Nasdaq, March 27, 2024 at 04:30 pm EDT

More quotes
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing therapeutics utilizing its long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. Its ProNeura continuous drug delivery system consists of a small, solid rod-shaped implant made from a mixture of ethylene-vinyl acetate (EVA), and a drug substance. Its first product, Probuphine (buprenorphine implant), is based on ProNeura technology, which is used for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 milligrams (mg) or less a day of oral buprenorphine. Its product pipeline includes the Kappa Opioid Receptor Agonist (TP-2021) Implant and Nalmefene Implant. Its TP-2021 is used for the treatment of moderate-to-severe chronic pruritus. Its Nalmefene Implant is used for the prevention of relapse in opioid use disorder (OUD) patients following detoxification from opioids.
More about the company
  1. Stock
  2. Equities
  3. Stock Titan Pharmaceuticals, Inc. - Nasdaq